Efficacy and Safety of Add-on Topical Timolol in the Management of Epidermal Growth Factor and Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase Inhibitor-induced Paronychia: a Prospective Randomized Open-labelled Trial

To assess the clinical efficacy of add-on topical timolol 0.5% eye drops to betamethasone valerate 0.1% for the treatment of EGFR-TKI and ALK-TKI induced paronychia.

Start Date09 Oct 2024

Sponsor / Collaborator

Queen Mary Hospital

IRCT20150825023753N23 / RecruitingPhase 3IIT

Comparison of fractional co2 laser therapy alone and with its combination with topical timolol or topical insulin in the treatment of acne scar, A randomized controlled clinical trial

Start Date31 Dec 2023

Sponsor / Collaborator

Shiraz University of Medical Sciences

NCT06140186 / RecruitingPhase 3IIT

Efficacy and Safety of add-on Topical Timolol in the Management of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-induced Paronychia: A Prospective Randomized Open-labelled Trial

This study would assess the clinical efficacy of add-on topical timolol 0.5% gel to betamethasone valerate 0.1% for the treatment of EGFR-TKI induced paronychia. Eligible patients, who develop paronychia (affecting fingernails, toenails or both), will be included in this study. They will be randomized in 1:1 ratio using computer-generated randomization list to receive either combination of topical timolol 0.5% gel and betamethasone valerate 0.1% lotion application twice daily or betamethasone valerate 0.1% lotion application twice daily. Patients in timolol combination treatment group will receive topical timolol 0.5% gel twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% lotion twice daily with occlsuion for 1 month. Patients in routine arm would receive the management according to routine clinical practice, including prescription of betamethasone valerate 0.1% lotion twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks , up to 12 weeks to see the effect.

Start Date01 Apr 2023

Sponsor / Collaborator

Queen Mary Hospital

100 Clinical Results associated with Timolol

100 Translational Medicine associated with Timolol

100 Patents (Medical) associated with Timolol

4,320

Literatures (Medical) associated with Timolol

01 Jan 2025·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Novel quantum dots-based assay for the determination of anti-hypertensive drugs minoxidil and timolol in different matrices

Article

Author: El Sharkasy, Mona E. ; Ahmed, Esraa S ; Bahgat, Eman A ; Belal, Fathalla ; Ahmed, Esraa S. ; Saleh, Hanaa ; El Sharkasy, Mona E ; Bahgat, Eman A.

The present work reports a sensitive, affordable, and ecologically friendly spectrofluorimetric method for the assessment of two antihypertensive medications, namely minoxidil and timolol. Blue-emitting sulfur and nitrogen co-doped carbon quantum dots (S,N-CQDs) were generated by exposing soluble starch and thiourea to a 15-minute microwave treatment. The so- prepared nanodots displayed fluorescence at 276/430 nm with a quantum yield of 22 %. Inspection of the so-prepared nano-sensor verified their doping with nitrogen and sulfur, and their size was in the range of 4.5-9.03 nm. The proposed method was found to be rectilinear in the range of 0.20-5.0 and 2.0-30.0 µg/mL, with LOQs of 0.16 and 0.82 µg/mL for minoxidil and timolol, respectively. The developed method was employed to assess the concentrations of minoxidil and timolol in their pharmaceutical formulations, with %recoveries varying between 99.00 % and 101.94 %, and low RSD values (less than 2 %). The high sensitivity of the developed method allowed its use for timolol measurement in artificial aqueous humor, with % recoveries between 97.60 %.and 101.57 %. The study further examined how each analyte interacted with the prepared dots, leading to a quenching of their fluorescence. Additionally, an interference study was utilized to evaluate the specificity of the proposed approach through determining analyte levels in the existence of common additives, co-formulated drugs, and co-administered drugs. The analytical eco-scale, GAPI and AGREE assessment techniques were utilized to confirm the suggested method greenness.

01 Dec 2024·Colloids and Surfaces B: Biointerfaces

Oxidized cellulose microneedle patch combined with vascular embolization and local delivery of timolol maleate for hemangiomas

Article

Author: Guo, Yiqun ; Li, Haibo ; Pang, Ningdong ; Liu, Lu ; Tan, Xiaoyun ; Niu, Chuanqiang ; Zhou, Zijun ; Jiang, Hua ; Liu, Lang ; Jiang, Yizhou

Hemangiomas are superficial tumors characterized by dense vascular structures that often affect the patient's aesthetic appearance due to the obvious red appearance on the skin. Current treatments, especially timolol maleate in the form of eye drops and hydrogels, suffer from low transdermal drug delivery rates, resulting in prolonged treatment time. To address this challenge, our study introduced a soluble microneedle patch with dextran as the main material to form microcatheters for sustained delivery of timolol maleate. In addition, we proposed a vascular embolization strategy to disrupt the blood supply in hemangiomas. Oxidized cellulose (C-cellulose) was selected for its excellent hemostatic properties. We incorporated C-cellulose into dextran microneedles to facilitate thrombosis in the vascular-rich areas of hemangiomas. The innovative microneedle patch we developed can penetrate the skin to a depth of 430 μm and dissolve rapidly within 3 minutes, ensuring direct drug delivery to the subcutaneous layer. Notably, the treated skin area regained its original appearance within two hours after treatment. In addition to excellent skin permeability and rapid dissolution, these patches significantly promoted apoptosis and inhibited cell migration in mouse hemangioendothelioma EOMA cells. Our results demonstrate that this approach not only achieves significant tumor inhibition in a mouse hemangioma model, but also represents a more effective, convenient, and non-invasive treatment option. Therefore, dextran/C-cellulose/timolol maleate microneedle patch (MNs/Timolol) has broad clinical application prospects in the treatment of hemangiomas, minimizing the risk of additional damage and improving treatment efficacy.

01 Dec 2024·Pharmacology Biochemistry and Behavior

Acute exercise performed during the late consolidation phase improves memory persistence by hippocampal protein synthesis and catecholamine modulation

Article

Author: de Souza, Anna Cecilia Perreto Vieira ; Lima, Karine Ramires ; Mello-Carpes, Pâmela Billig ; Gomes, Gabriela Cristiane Mendes ; Perretto, Anna Cecilia ; Rosa, Ana Carolina de Souza da ; Sigaran, Gabriela Jaques ; de Souza da Rosa, Ana Carolina

Memory persistence is a crucial aspect of long-term memory (LTM) and involves late consolidation processes that modulate memory stability over time. Acute physical exercise (PE) has emerged as a potential strategy to modulate memory consolidation and enhance memory persistence. While its effects have been extensively explored in the early consolidation phase, its impact on the late phase remains unexplored. In this study, we investigated the effects and mechanisms of an acute PE on the late consolidation window of novel object recognition (NOR) memory in rats. A 30-minute running session applied 11 h after NOR memory acquisition significantly increased memory persistence for at least 7 days. The inhibition of hippocampal protein synthesis immediately after acute PE using anisomycin (a ribosomal inhibitor) or rapamycin (an mTOR pathway inhibitor) impaired the effect of PE on memory persistence. Animals only presented memory 1 day after acquisition. The same effect was observed with the inhibition of beta-adrenergic receptors by timolol. Although there were no differences between the groups' comparison, blocking D1/D5 receptors after acute PE resulted in a lack of memory persistence in the dichotomous testing (remember/non-remember). Therefore, our exploration of the mechanisms underlying this enhancement revealed the involvement of protein synthesis and the requirement of beta-adrenergic and dopaminergic D1/D5 receptors in the dorsal hippocampus. These findings provide valuable insights into PE as a potential memory modulator, contributing to expanding our understanding of memory consolidation dynamics and acute PE effects.

News (Medical) associated with Timolol

31 Oct 2024

·www.prnewswire.com

Formosa Pharmaceuticals and DÁVI Farmacêutica Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain

TAIPEI, Oct. 31, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with DÁVI Farmacêutica ("DÁVI") in Portugal, for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a marketed innovative medicine for the treatment of inflammation and pain following ocular surgery. DÁVI is a trusted partner of Pharmathen Global Holding B.v., AZAD Pharma AG, NTC S.r.l. and Pfizer through marketing and promotion of Xalacom© (Latanoprost + Timolol) and Xalatan© (Latanoprost) for more than 12 years. DÁVI is one of the key players in the Portuguese Market, with over 100 years' history in the distribution and promotion of branded ophthalmology products. Clobetasol propionate ophthalmic suspension, 0.05% (APP13007), approved by the U.S. Food and Drug Administration (FDA) in March, 2024, was recently launched in the United States in September, 2024. The DÁVI licensing agreement includes upfront, commercialization milestones, and sales milestones, with additional considerations throughout the term of the agreement. APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform. The novel formulation enables a convenient and straightforward dosing regimen (twice daily for 14 days) while providing rapid and sustained relief of inflammation and pain. In a recent survey of 100 ophthalmic surgeons, rapid resolution of pain (~80% pain-free four days post-surgery) and low incidence of adverse events (<2%) were highlighted as key drivers to prescribing APP13007. APP13007 anticipates significant potential in Portugal, which has around 90,000 cataract surgeries, annually, as reported by Eurostat. "This partnership with DÁVI Farmacêutica, marks our first entry into a competitive EU market, opening the door for growth into other EU territories. DÁVI's experience and commitment to novel ophthalmic therapies is steadily apparent and Formosa Pharma appreciates their recognition of APP13007 as a worthy offering to patients recovering from ocular surgery." said Erick Co, President and CEO of Formosa Pharmaceuticals. Rui Alves, Business Development Manager of DÁVI Farmacêutica, stated, "We are excited at DÁVI to be partnering with Formosa and have the opportunity to offer this cutting-edge drug and technology to our ophthalmologists and patients, reinforcing our strong position in the market and the commitment to enhance the well-being of our people." About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which APP13007 was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration. Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in safety, delivery, and penetration to target tissues. For more details about Formosa Pharma and APNT®, visit . About DÁVI Farmacêutica DÁVI Farmacêutica, is a century-old company and one of the key players in ophthalmology and ENT segments in Portugal. The company's core activities are the distribution & promotion of branded medicines with significant partnerships with major multinational pharmaceutical companies. Our daily mission is to give our patients the best option available in the market, making their lives better. To know more about DÁVI Farmacêutica, visit . SOURCE Formosa Pharmaceuticals Inc., WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/inDrug Approval

21 Mar 2024

·www.prnewswire.com

Landmark Non-inferiority Clinical Trial Demonstrates Nanodropper's Positive Impact on Glaucoma Treatment

A new study published in Ophthalmology demonstrated no clinically significant difference in IOP with microdrops with the Nanodropper® Adaptor versus conventional eyedrops of the glaucoma treatment timolol maleate 0.5%. ROCHESTER, Minn., March 21, 2024 /PRNewswire/ -- Nanodropper, Inc., an ophthalmic device company that created the eyedrop volume-reducing Nanodropper® Adaptor, announced today that its clinical trial "An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper" was published in the journal Ophthalmology. Continue Reading This was a prospective, multicenter, randomized, parallel-group, single-masked, active-controlled, non-inferiority trial. The trial enrolled glaucoma patients and demonstrated there was no clinically significant difference in the intraocular pressure (IOP)-lowering effects of microdrops administered with the Nanodropper Adaptor compared to conventional eyedrops of timolol, an eyedrop medication commonly used to treat glaucoma. This was observed at all time points throughout the eight-hour study. Subjects in the microdrops arm also experienced a significantly smaller decrease in heart rate compared to those that received conventional drops, demonstrating there could be an enhanced safety profile of using a microdrop of timolol compared to a conventionally-sized eyedrop. Landmark Non-inferiority Clinical Trial Demonstrates Nanodropper's Positive Impact on Glaucoma Treatment Post this "We are thrilled, albeit not surprised, by these encouraging results demonstrating the Nanodropper Adaptor's capacity to improve patient safety," said Jenny Steger, PhD, Chief Scientific Officer of Nanodropper. "Thousands of eyecare clinics in the U.S., and tens of thousands of patients worldwide, are already utilizing the Nanodropper to great effect. This study reflects the benefits these patients have been experiencing." The Nanodropper Adaptor is the first and only sterile adaptor for eyedrop bottles that reduces eyedrop volume to just what the eye can absorb, significantly reducing medication waste and financial barriers for patients and clinics. This study's results suggest the Nanodropper Adaptor's microdrops provide patients an enhanced safety improvement over conventional eyedrops while maintaining the efficacy of the medication. "Eyedrop size has not seriously been commercially addressed in the past," said Alan L. Robin, MD, corresponding author on the publication and a global leader in glaucoma research and treatment for decades. He is a charter member of the American Glaucoma Society, its first executive vice president, and sits on Nanodropper's Medical Advisory Board. His previous research on microvolume delivery of eyedrops directly inspired the creation of the Nanodropper Adaptor. "I believe microvolume delivery technologies may offer solutions in the form of less waste, increased patient savings, and hopefully better safety profiles for many topical ophthalmic medications," said Dr. Robin. "Nanodropper is the first commercially available potential solution to this long-standing problem." To review the study in Ophthalmology, the full-text version can be viewed at this link. Where are Nanodropper Adaptors available? Nanodroppers are available at , and in over 2,500 eyecare clinics across all 50 states, Puerto Rico, and the U.S. Virgin Islands. Nanodropper Adaptors have also been made available via the company's Give the Gift of Vision charitable program to U.S.-based patients who cannot afford to purchase one, and internationally through more than a dozen nonprofit partners providing access to eyecare on a global scale. Contact: Mackenzie Andrews [email protected] SOURCE Nanodropper

Clinical Result

21 Mar 2024

·www.prnewswire.com

OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth

SHANGHAI, March 21, 2024 /PRNewswire/ -- On the evening of March 21st, OcuMension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "OcuMension" or the "Company") disclosed its 2023 annual performance report. The company achieved a total operating income of RMB 246.4 million for the full year, a year-on-year increase of 55.0%; with a comprehensive gross profit of RMB 144.4 million, representing a year-on-year increase of 40.3%. During the reporting period, the company's major operating indicators performed well, benefiting from rapid growth in sales revenue and further improvement in operational efficiency and cost control. Enhanced Product Matrix, Rapid Expansion Leveraging First-mover Advantage Adhering to the development philosophy of "providing world-class holistic solutions for pharmaceuticals," OcuMension has consistently devoted itself to identifying, developing, and commercializing innovative or best-in-class ophthalmic therapies. The company continuously enriches and expands its product matrix to meet the significant demand gap in Chinese ophthalmic medical care while maintaining its leading position in the ophthalmic track. A diversified product matrix has laid the foundation for the company's steady growth. Leveraging its strong corporate strength, the company possesses a leading ophthalmic pharmaceutical platform with various drugs for both anterior and posterior segments, providing strong support for the company's development. Among them, the company's main products such as Ouqin (sodium hyaluronate eye drops), Emidin (timolol maleate eye drops), and Shilida (latanoprost eye drops) have all maintained steady growth. Additionally, as one of OcuMension's outstanding products, OT-401(YUTIQ)® for the treatment of chronic non-infectious uveitis was successfully included in the medical insurance catalog in December of last year. It is reported that OT-401(YUTIQ)® completed the first domestic injection in December 2022, breaking the deadlock in the treatment of uveitis in China at that time, filling the treatment gap domestically, alleviating the burden on patients to the greatest extent, and marking the formal entry of the product into ophthalmic clinical applications. It is worth noting that since OT-401(YUTIQ)® officially entered the medical insurance catalog on January 1st of this year, the company has rapidly promoted its medical insurance landing work nationwide with its comprehensive commercialization capabilities, bringing better and more affordable treatment options for uveitis patients. As of the disclosure date of the report, the terminal injection volume of OT-401(YUTIQ)® has exceeded the total for the previous year and is expected to continue to rapidly expand. Overcoming Technological Peaks, Strengthening Self-defense with R&D Strength To break the previous dominance of foreign capital in the Chinese ophthalmic drug market, the company continues to increase its investment in research and development, focusing on dual-source innovation, optimizing registration and development, promoting commercialization, and adhering to high-quality technical standards throughout the entire production cycle to ensure product safety, efficacy, and quality control. With years of technological accumulation and industrial experience, in 2023, the company achieved several milestone breakthroughs with the assistance of clinical PI, including the submission of NDA for OT-1001 (timolol hydrochloride eye drops) accepted by CDE and included in the priority review program; completion of global patient enrollment for Phase III MRCT of OT-101 (atropine sulfate eye drops); completion of real-world studies for OT-502 (dexamethasone implant), currently in the Pre-NDA stage; the completion of patient enrollment for Phase II clinical trials of OT-202 (tyrosine kinase inhibitor), a self-developed drug for dry eye syndrome, in 25 experimental centers, with a total of over 700 patients enrolled during the year. This not only enriches the company's product pipeline but also provides more high-quality treatment options for patients. The edge of technology stems from the strength of research and development behind it. Throughout 2023, the company invested a total of RMB 123.8 million in research and development, injecting strong momentum into the company's continued development. Meanwhile, the company also focuses on building a clinical research platform and constructing a research and development team to enrich the company's product pipeline and produce multi-level products that better meet patient needs. So far, the company has a total of 25 drug assets for both anterior and posterior segments, with 12 products already commercialized, covering both anterior and posterior segments and forming a strong product matrix in the fields of anti-allergy and glaucoma. Among them, five products in the company's pipeline are still in Phase III clinical trials, making it one of the companies with the highest number of Phase III clinical trials for innovative drugs in the Chinese ophthalmic drug market. It is noteworthy that the company has made breakthrough progress in the research and development of the myopia drug Atropine recently. Faced with the challenge of stability, the company cleverly solved the long-term storage stability problem of low-concentration atropine sulfate solution by using a dual-chamber device of reconstitution solution and freeze-dried powder. Currently, the company's self-developed product OT-101-S (0.01% and 0.05% atropine sulfate eye drops) has had its Phase III clinical trial application accepted by CDE in China. Accelerated Commercialization Process Provides Strong Support for Sales Revenue on the Sales Side As one of the powerful driving forces for terminal sales, commercialization has also shown remarkable performance for OcuMension in terms of product hospitalization. In 2023, with a complete product pipeline, the company continued to expand hospital coverage and accelerate product hospitalization. Currently, the company has formed a nationwide sales network, covering 1558 tertiary hospitals, with a commercial team of over 230 people. On this basis, the company deeply explores the commercial penetration of strong products such as Shilida and Emidin, achieving rapid growth in sales revenue. In addition, under the full play of national fiscal funds' guiding role in the development of innovative drugs, more approval resources will tilt towards high-value innovative drugs. With the company's increasingly mature commercialization process and the policy-driven tailwind, the company's image in the secondary market, previously underestimated, is expected to change. Within the month, the Hong Kong stock innovative drug sector has seen a full-scale increase, and the company gradually returned to a benign growth track in this round of valuation restoration of Hong Kong stock pharmaceuticals. In the future, driven by multiple factors such as aging, electronic lifestyle, increasing medical awareness among patients, and rising resident payment levels, China's ophthalmic market has tremendous development potential. The company will rely on its first-mover advantage to rapidly enhance its competitiveness and penetration in the domestic market, while actively expanding overseas markets to enhance the company's international influence. By continuously deepening hospital cooperation, optimizing sales network layout, the company will further improve product coverage, providing more patients with high-quality and efficient medical services. Chasing light and encountering, forging ahead. The development of innovative drugs in the field of Chinese ophthalmology is arduous but promising. With the continuous improvement in market recognition of the company's products, OcuMension will continue to uphold the development philosophy of innovation-driven and quality-oriented, continuously strengthen research and development investment, introduce more innovative and competitive products, strive to lead the market, and provide greater returns for investors. SOURCE OcuMension

Phase 3Financial StatementNDA

100 Deals associated with Timolol

External Link

KEGG	Wiki	ATC	Drug Bank
D08600	Timolol	S01ED01 C07AA06	DB00373

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertension	US	Thea Pharma, Inc.	31 Mar 1995

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Eye Diseases	Phase 2	US	Betaliq, Inc.Startup	30 Jan 2022
Dry Eye Syndromes	Phase 2	-	Novaliq GmbH	-
Glaucoma	Discovery	US	Alcon Research Ltd.	01 Jan 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02822729 (RENGE, Pubmed \| Jpn J Ophthalmol)	Phase 3	Ocular Hypertension \| Glaucoma, Open-Angle	125	Omidenepag isopropyl 0.002%	vxvqlgobuu(zhalnvnkie) = incidence: monotherapy [Groups 1 and 2], 18.8%; concomitant [Group 3], 45.0% uyjigrsgng (oqtvxdznzf ) View more	-	08 Sep 2021
				Omidenepag isopropyl 0.002% + Timolol 0.5%
APAO2021	Not Applicable	-	-	Topical Timolol Gel 0.5%	vtxyhkryrw(ztunkhumpo) = There were no obvious systemic or ocular side effects. rdddnrrzbw (gezecrouhu ) View more	-	05 Sep 2021
EDEN consortium (ARVO2021)	Not Applicable	-	106	Latanoprost	(kzwarobsga) = laxdlogkec ycysajywwj (bsvcdtzsmx )	Negative	01 Jun 2021
				Timolol	(kzwarobsga) = bczfluzmxv ycysajywwj (bsvcdtzsmx )
NCT03836664 (CTgov)	Phase 2	Migraine Disorders	25	Timolol (All Participants Post Timolol)	toskszkizy(vcwjredmnv) = djetjhmzfk sfssfjdeom (oozbdusztg, qdvdfmcqyk - qjopjanjgd) View more	-	02 Jul 2019
				placebo+Timolol (All Participants Post Placebo)	toskszkizy(vcwjredmnv) = jswwsgwvwk sfssfjdeom (oozbdusztg, fmziktssml - zvdjfncguu) View more
NCT01677507 (ARVO2019)	Phase 4	-	121	Timolol 0.5%	wdkmnnhrbg(dddytsnzfv) = ljnvaknekg xrxlngwhjw (xpsfhfcojw, 7.9)	Positive	01 Jul 2019
				Latanoprost 0.005%	wdkmnnhrbg(dddytsnzfv) = drxptlsnjr xrxlngwhjw (xpsfhfcojw, 7.9)
NCT02630719 (CTgov)	Not Applicable	Migraine Disorders	10	Timolol eye drops (Timolol Eye Drops)	miqsgnxhhv(iegqazuzrf) = xbrrunazqo qatigrfwuk (yduraxukbc, pxlwsowtze - nbucbieykg) View more	-	15 May 2019
				Artificial tears (Artificial Tears)	miqsgnxhhv(iegqazuzrf) = xummwnreqz qatigrfwuk (yduraxukbc, fibnimwefq - ftwrniurnb) View more
NCT02742649 (CTgov)	Phase 1/2	Glaucoma, Open-Angle	55	Fixed Combination+Timolol 0.5% (Fixed Combination (FC) Ocular Insert)	ltgfgfhupq(xlerupblqx) = qgengrjwco ytlqrivfwb (jhhlfllixo, yatetsnlix - uxsdjapocd) View more	-	31 Dec 2018
				Placebo Segment+Timolol 0.5%+Bimatoprost (Bimatoprost Ocular Insert)	ltgfgfhupq(xlerupblqx) = myrwrurqun ytlqrivfwb (jhhlfllixo, solvhperry - ebzsopwzmq) View more
NCT01147601 (CTgov)	Early Phase 1	Capillary Hemangioma	6	topical 0.5% Timolol (Topical 0.5% Timolol)	pzjibksaae(pvtvjzrnoy) = picqxkaqoc wlxhznavsn (ffzrmnftnt, meykxcatqj - gtqecihzay) View more	-	05 Jul 2017
				Control (placebo) group (Placebo)	pzjibksaae(pvtvjzrnoy) = ihnlxuyfsw wlxhznavsn (ffzrmnftnt, zqrefqrqxr - atcpcrxazf) View more
NCT02097719 (CTgov)	Phase 4	Glaucoma	100	hypromellose 0.3%+bimatoprost 0.01% (Bimatoprost 0.01% and Hypromellose 0.3%)	qnlbvidhbe(nrscizissb) = ltqwrkqljl ufwvorbkoe (wsowaziboc, hekufvlpol - nxefletoek) View more	-	14 Jan 2016
				timolol 0.5%+travoprost 0.004% (Travoprost 0.004% and Timolol 0.5%)	qnlbvidhbe(nrscizissb) = joseoppeis ufwvorbkoe (wsowaziboc, naxfkwopbd - pfluhgqdif) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis